Preskoči na vsebino

Onkologija

Management and Optimization of Hemostasis

Antifibrinolytic Agents

Epsilon aminocaproic acid prevents bleeding in severely thrombocytopenic patients with hematological malignancies. (odpre novo okno)

Antun AG, Gleason S, Arellano M, Langston AA, McLemore ML, Gaddh M, el Rassi F, Bernal-Mizrachi L, Galipeau J, Heffner LT Jr, Winton EF, Khoury HJ.

Vir‎: Cancer 2013;119(21):3784-7.

Indeksirano‎: PubMed 23921838

DOI‎: 10.1002/cncr.28253

https://www.ncbi.nlm.nih.gov/pubmed/23921838 (odpre novo okno)

Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. (odpre novo okno)

Avvisati G, ten Cate JW, Büller HR, Mandelli F.

Vir‎: Lancet 1989;334(8655):122-4.

Indeksirano‎: PubMed 2567893

https://www.ncbi.nlm.nih.gov/pubmed/2567893 (odpre novo okno)

Epsilon aminocaproic acid reduces transfusion requirements in patients with thrombocytopenic hemorrhage. (odpre novo okno)

Kalmadi S, Tiu R, Lowe C, Jin T, Kalaycio M.

Vir‎: Cancer 2006;107(1):136-40.

Indeksirano‎: PubMed 16708357

DOI‎: 10.1002/cncr.21958

https://www.ncbi.nlm.nih.gov/pubmed/16708357 (odpre novo okno)

Aminocaproic acid use in hospitalized patients with hematological malignancy: a case series. (odpre novo okno)

Marshall A, Li A, Drucker A, Dzik W.

Vir‎: Hematol Oncol 2016;34(3):147-53.

Indeksirano‎: PubMed 25641349

DOI‎: 10.1002/hon.2189

https://www.ncbi.nlm.nih.gov/pubmed/25641349 (odpre novo okno)

A controlled trial of tranexamic acid therapy for the reduction of bleeding during treatment of acute myeloid leukemia. (odpre novo okno)

Shpilberg O, Blumenthal R, Sofer O, Katz Y, Chetrit A, Ramot B, Eldor A, Ben-Bassat I.

Vir‎: Leuk Lymphoma 1995;19(1-2):141-4.

Indeksirano‎: PubMed 8574160

DOI‎: 10.3109/10428199509059668

https://www.ncbi.nlm.nih.gov/pubmed/8574160 (odpre novo okno)

Acute promyelocytic leukaemia and acquired alpha-2-plasmin inhibitor deficiency: a retrospective look at the use of epsilon-aminocaproic acid (Amicar) in 30 patients. (odpre novo okno)

Wassenaar T, Black J, Kahl B, Schwartz B, Longo W, Mosher D, Williams E.

Vir‎: Hematol Oncol 2008;26(4):241-6.

Indeksirano‎: PubMed 18613223

DOI‎: 10.1002/hon.867

https://www.ncbi.nlm.nih.gov/pubmed/18613223 (odpre novo okno)

Recombinant Activated Factor VII (rFVIIa)

Use of Novoseven for arsenic trioxide-induced bleeding in PML. (odpre novo okno)

Alimoghaddam K, Ghavamzadeh A, Jahani M.

Vir‎: Am J Hematol 2006;81(9):720.

Indeksirano‎: PubMed 16804937

DOI‎: 10.1002/ajh.20713

https://www.ncbi.nlm.nih.gov/pubmed/16804937 (odpre novo okno)

Control of bleeding caused by thrombocytopenia associated with hematologic malignancy: an audit of the clinical use of recombinant activated Factor VII. (odpre novo okno)

Brenner B, Hoffman R, Balashov D, Shutluko E, Čulić SD, Nizamoutdinova E.

Vir‎: Clin Appl Thromb Hemost 2005;11(4):401-10.

Indeksirano‎: PubMed 16244765

https://www.ncbi.nlm.nih.gov/pubmed/16244765 (odpre novo okno)

The potential role of recombinant activated FVII in the management of critical hemato-oncological bleeding: a systematic review. (odpre novo okno)

Franchini M, Veneri D, Lippi G.

Vir‎: Bone Marrow Transplant 2007;39(12):729-35.

Indeksirano‎: PubMed 17417659

DOI‎: 10.1038/sj.bmt.1705670

https://www.ncbi.nlm.nih.gov/pubmed/17417659 (odpre novo okno)

Effective hemostasis with rFVIIa treatment in two patients with severe thrombocytopenia and life-threatening hemorrhage. (odpre novo okno)

Gerotziafas GT, Zervas C, Gavrielidis G, Tokmaktsis A, Hatjiharissi E, Papaioannou M, Lazaridou A, Constantinou N, Samama MM, Christakis J.

Vir‎: Am J Hematol 2002;69(3):219-22.

Indeksirano‎: PubMed 11891811

https://www.ncbi.nlm.nih.gov/pubmed/11891811 (odpre novo okno)

Use of recombinant activated factor VII in a Jehovah's Witness patient. (odpre novo okno)

Hsieh A, Cheong I.

Vir‎: Am J Emerg Med 2007;25(9):1085.e1-2.

Indeksirano‎: PubMed 18022514

DOI‎: 10.1016/j.ajem.2007.03.007

https://www.ncbi.nlm.nih.gov/pubmed/18022514 (odpre novo okno)

Clinical experience with recombinant factor VIIa in patients with thrombocytopenia. (odpre novo okno)

Kristensen J, Killander A, Hippe E, Helleberg C, Ellegard J, Holm M, Kutti J, Mellqvist UH, Johansson JE, Glazer S, Hedner U.

Vir‎: Haemostasis 1996;26 Suppl 1:159-64.

Indeksirano‎: PubMed 8904193

https://www.ncbi.nlm.nih.gov/pubmed/8904193 (odpre novo okno)

Effective treatment of life-threatening bleeding with recombinant activated factor VII in a patient with acute promyelocytic leukaemia. (odpre novo okno)

Zver S, Andoljšek D, Černelč P.

Vir‎: Eur J Haematol 2004;72(6):455-6.

Indeksirano‎: PubMed 15128428

DOI‎: 10.1111/j.1600-0609.2004.00237.x

https://www.ncbi.nlm.nih.gov/pubmed/15128428 (odpre novo okno)

Coagulation Factor Concentrates

Management of bleeding complications of hematologic malignancies. (odpre novo okno)

Green D.

Vir‎: Semin Thromb Hemost 2007;33(4):427-34.

Indeksirano‎: PubMed 17525900

DOI‎: 10.1055/s-2007-976178

https://www.ncbi.nlm.nih.gov/pubmed/17525900 (odpre novo okno)

Management of bleeding in patients with advanced cancer. (odpre novo okno)

Pereira J, Phan T.

Vir‎: Oncologist 2004;9(5):561-70.

Indeksirano‎: PubMed 15477642

DOI‎: 10.1634/theoncologist.9-5-561

https://www.ncbi.nlm.nih.gov/pubmed/15477642 (odpre novo okno)

Desmopressin

Desmopressin and other synthetic vasopressin analogues in cancer treatment. (odpre novo okno)

Gomez DE, Ripoll GV, Girón S, Alonso DF.

Vir‎: Bull Cancer 2006;93(2):E7-12.

Indeksirano‎: PubMed 16517412

https://www.ncbi.nlm.nih.gov/pubmed/16517412 (odpre novo okno)